

## Nomination Committee appointed at Iconovo AB

**At the Annual General Meeting of 17 May 2022, it was resolved that Iconovo AB shall have a Nomination Committee consisting of four members representing the four largest shareholders as of 30 September each year.**

**The Nomination Committee for the 2024 Annual General Meetings consists of:**

Mats Johansson, appointed by Mats Johansson and holding company, and Chairman of the Nomination Committee

Gerald Engström;

Orest Lastow, appointed by Lastow Consulting AB;

Stefan Berger, appointed by Eiffel Investment Group;

Participates as co-opted;

Gunnar Gårdemyr, Chairman of the Board

The Nomination Committee's overarching responsibility for the 2024 Annual General Meeting is to present suitable candidates for the positions of Board Chair, Board members and auditors of the Company, and to propose their remuneration.

**The Nomination Committee shall prepare proposals in the following matters to be submitted to the Annual General Meeting for decision:**

proposal for Chair of the AGM,

proposal for the number of AGM-elected Board members and, where applicable, number of auditors,

proposal for remuneration to non-employed members of the Board and to non-employed members of the various committees of the Board,

proposal for remuneration to the auditors,

proposals for election of Board Chair, other members of the Board and, where applicable, auditors,

proposals for guidelines for appointing members to the Nomination Committee and for the Nomination Committee's assignments.

Shareholders who wish to submit proposals to the Nomination Committee can contact the Nomination Committee by email at [gunnar.gardemyr@gmail.com](mailto:gunnar.gardemyr@gmail.com).

In order for the Nomination Committee to process received proposals with sufficient care, these should be received by the Nomination Committee by 1 March 2024.

For more information, please contact:

Gunnar Gårdemyr, Chairman of the Board, [gunnar.gardemyr@gmail.com](mailto:gunnar.gardemyr@gmail.com).

### About Iconovo

---

Iconovo (Nasdaq First North Growth Market: ICO) develops new inhaled medicinal products in collaboration with international pharmaceutical companies. The company provides several types of patent-protected inhalers that can generate significant commercial opportunities in the development of novel pharmaceuticals and vaccines and at patent expirations for established pharmaceuticals. The most advanced project is a generic version of the asthma and COPD product Symbicort® which is expected to reach the market in 2025. Iconovo plans to market this product in the Nordic region through its subsidiary Iconovo Pharma, while the company's partner Amneal Pharmaceuticals has the rights in other parts of Europe and the United States. Certified Adviser is Erik Penser Bank AB.

### Attachments

---

[Nomination Committee appointed at Iconovo AB](#)